Joseph C Anderson1,2, Carolyn B Morris2, Douglas J Robertson1,2, Elizabeth L R Barry2, Jane C Figueiredo3, Marcia Cruz-Correa4, Roberd M Bostick5, Dennis J Ahnen6, John A Baron2,7. 1. Department of Veterans Affairs Medical Center, White River Junction, VT. 2. The Geisel School of Medicine at Dartmouth College, Hanover, NH. 3. Department of Preventive Medicine, Keck School Of Medicine, University of Southern California, Los Angeles, CA. 4. University of Puerto Rico San Juan, Puerto Rico. 5. Department of Epidemiology, Rollins School of Public Health, and Winship Cancer Institute, Emory University, Atlanta, GA. 6. University of Colorado School of Medicine and Gastroenterology of the Rockies, Denver/Boulder, CO. 7. University of North Carolina at Chapel Hill Chapel Hill, NC.
Abstract
BACKGROUND: Recent data suggest that adenoma size and number are more important predictors of metachronous colorectal neoplasia than advanced histology. Furthermore, there is poor reproducibility in diagnosing advanced histology; high-grade dysplasia and villous histology. Therefore we developed a new metric, adenoma bulk, the sum of diameters of all baseline adenomas, regardless of advanced features. GOAL: Compare the predictive value for metachronous advanced neoplasia of adenoma bulk to conventional paradigm. STUDY: Data were collected prospectively in a multicenter adenoma-chemoprevention trial (2004 to 2013). For the conventional paradigm, high-risk baseline findings were defined as ≥3 adenomas, large adenomas (≥1 cm) or adenomas with villous components or high-grade dysplasia. Adenoma bulk was examined across quartiles and as a continuous variable. Predictive characteristics (sensitivities, specificities, c-statistics) for metachronous advanced neoplasia using conventional criteria and adenoma bulk were calculated. receiver operator characteristic curves were computed using logistic regression. RESULTS: In total, 1948 adults had index and follow-up colonoscopies (mean follow-up, 45.2 mo). Those with an adenoma bulk ≥10 mm (4th quartile) had a higher metachronous advanced neoplasia risk (14.4% vs. 6.9-8.2% in lower 3 quartiles; P=0.0002). The c-statistics and sensitivities (specificity fixed at 0.73) for the adenoma bulk and conventional models were 0.587 and 0.563 (P=0.17) and 0.396 and 0.390, respectively. CONCLUSIONS: Categorizing sporadic adenoma patients as high versus low risk for metachronous advanced neoplasia by adenoma bulk of <versus ≥10 mm may be comparably predictive as conventional paradigm and simplifies risk stratification by obviating need for additional histology regarding extent of villous component or degree of dysplasia in resected polyps. The adenoma bulk metric and the 10 mm cutoff in particular would have to be validated in other populations before it can be used in clinical practice.
BACKGROUND: Recent data suggest that adenoma size and number are more important predictors of metachronous colorectal neoplasia than advanced histology. Furthermore, there is poor reproducibility in diagnosing advanced histology; high-grade dysplasia and villous histology. Therefore we developed a new metric, adenoma bulk, the sum of diameters of all baseline adenomas, regardless of advanced features. GOAL: Compare the predictive value for metachronous advanced neoplasia of adenoma bulk to conventional paradigm. STUDY: Data were collected prospectively in a multicenter adenoma-chemoprevention trial (2004 to 2013). For the conventional paradigm, high-risk baseline findings were defined as ≥3 adenomas, large adenomas (≥1 cm) or adenomas with villous components or high-grade dysplasia. Adenoma bulk was examined across quartiles and as a continuous variable. Predictive characteristics (sensitivities, specificities, c-statistics) for metachronous advanced neoplasia using conventional criteria and adenoma bulk were calculated. receiver operator characteristic curves were computed using logistic regression. RESULTS: In total, 1948 adults had index and follow-up colonoscopies (mean follow-up, 45.2 mo). Those with an adenoma bulk ≥10 mm (4th quartile) had a higher metachronous advanced neoplasia risk (14.4% vs. 6.9-8.2% in lower 3 quartiles; P=0.0002). The c-statistics and sensitivities (specificity fixed at 0.73) for the adenoma bulk and conventional models were 0.587 and 0.563 (P=0.17) and 0.396 and 0.390, respectively. CONCLUSIONS: Categorizing sporadic adenomapatients as high versus low risk for metachronous advanced neoplasia by adenoma bulk of <versus ≥10 mm may be comparably predictive as conventional paradigm and simplifies risk stratification by obviating need for additional histology regarding extent of villous component or degree of dysplasia in resected polyps. The adenoma bulk metric and the 10 mm cutoff in particular would have to be validated in other populations before it can be used in clinical practice.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Bradley W Anderson; Thomas C Smyrk; Kari S Anderson; Douglas W Mahoney; Mary E Devens; Seth R Sweetser; John B Kisiel; David A Ahlquist Journal: Gastrointest Endosc Date: 2015-08-28 Impact factor: 9.427
Authors: Douglas K Rex; Philip S Schoenfeld; Jonathan Cohen; Irving M Pike; Douglas G Adler; M Brian Fennerty; John G Lieb; Walter G Park; Maged K Rizk; Mandeep S Sawhney; Nicholas J Shaheen; Sachin Wani; David S Weinberg Journal: Gastrointest Endosc Date: 2014-12-02 Impact factor: 9.427
Authors: John A Baron; Elizabeth L Barry; Leila A Mott; Judy R Rees; Robert S Sandler; Dale C Snover; Roberd M Bostick; Anastasia Ivanova; Bernard F Cole; Dennis J Ahnen; Gerald J Beck; Robert S Bresalier; Carol A Burke; Timothy R Church; Marcia Cruz-Correa; Jane C Figueiredo; Michael Goodman; Adam S Kim; Douglas J Robertson; Richard Rothstein; Aasma Shaukat; March E Seabrook; Robert W Summers Journal: N Engl J Med Date: 2015-10-15 Impact factor: 91.245
Authors: Joseph C Anderson; Rajeev Attam; Zvi Alpern; Catherine R Messina; Patricia Hubbard; Roger Grimson; Peter F Ells; Douglas L Brand Journal: Am J Gastroenterol Date: 2003-12 Impact factor: 10.864
Authors: Bernard Denis; Carol Peters; Catherine Chapelain; Isabelle Kleinclaus; Anne Fricker; Richard Wild; Bernard Augé; Isabelle Gendre; Philippe Perrin; Denis Chatelain; Jean François Fléjou Journal: Eur J Gastroenterol Hepatol Date: 2009-10 Impact factor: 2.566
Authors: Dipti Mahajan; Erinn Downs-Kelly; Xiuli Liu; Rish K Pai; Deepa T Patil; Lisa Rybicki; Ana E Bennett; Thomas Plesec; Oscar Cummings; Douglas Rex; John R Goldblum Journal: Am J Surg Pathol Date: 2013-03 Impact factor: 6.394